CoreRx Adds Precision Powder Microdosing System to its Development Capabilities

CoreRx recently announced it has further enhanced its offering by adding an Xcelodose precision powder microdosing system to its Product Development capabilities in response to client requirements for preclinical and early phase clinical GMP supply. The Xcelodose decreases processing time and API use, generating significant cost savings to clients.

For simple formulations of API or powder-in-capsule, the Xcelodose system can significantly reduce processing time and API usage resulting in cost savings when compared to hand-filling options.

“CoreRx is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times,” said Mark Licarde, CoreRx’s VP of Manufacturing. “While CoreRx has always offered API in capsule, we now see examples of some clients maintaining this approach through to Phase II studies in an attempt to compress their overall development timelines, requiring significant quantities of capsules for which an automated solution is best. CoreRx is the only CRO in the world with a full set of Xcelodose change parts all the way down to size 9.”

The Xcelodose system, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or API directly into capsules with a high level of accuracy. The Xcelodose system can dispense amounts as low as 100 micrograms and up to 100 milligrams and beyond, into capsules from size 00 to size 9. Dosing directly into capsules can reduce the amount of API required. Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.

CoreRx focuses on supporting and streamlining the drug development process for biotechnology and pharmaceutical innovators by offering services such as preformulation/formulation development, analytical development, clinical manufacturing, and validation engineering. It has a proven track record and extensive expertise providing comprehensive drug development services to biotechnology and pharmaceutical companies worldwide. CoreRx, Inc. is a CGMP-compliant contract development and manufacturing facility. From its inception in 2006, CoreRx has been dedicated to solving scientific problems and providing expert pharmaceutical services to businesses required to meet the growing demand of pharmaceutical companies.

Headquartered in Tampa, FL, the company provides quality pharmaceutical formulation development, clinical trial material (Phase I, II, and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.